[A phase III trial comparing the antiemetic activity of tetracosactide with dexamethasone in combination with metoclopramide, diphenhydramine and clorazepate during chemotherapy including cisplatin].
In order to compare the safety and the antiemetic effectiveness of tetracosactide (TCS) or beta 1,24 ACTH with those of dexamethasone (DXM) as an adjunct to high-dose metoclopramide, diphenhydramine and clorazepate, 33 patients receiving cisplatin based cancer chemotherapy were enrolled in a double-blind cross-over clinical trial. TCS and DXM were given intravenously, respectively at a dose of 2 mg and 20 mg, and concurrently to the cisplatin infusion. No statistically significant difference was noted between the two drugs with regard to efficacy or side effects. We conclude that TCS can serve as a substitute for DXM in combination antiemetic regimens for management of cisplatin-induced nausea and vomiting.
Culine
S
S
Département de médecine, Institut Gustave-Roussy, Villejuif, France.
Azab
M
M
Pietri
F
F
Ghosn
M
M
Ben Amor
B
B
Lupera
H
H
Theodore
C
C
Renaux
J
J
Droz
J P
JP
D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000009:adverse effects* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003009:Clorazepate Dipotassium / Q000008:administration & dosage; D003366:Cosyntropin / Q000008:administration & dosage*; D003907:Dexamethasone / Q000008:administration & dosage*; D004155:Diphenhydramine / Q000008:administration & dosage; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D006801:Humans; D008787:Metoclopramide / Q000008:administration & dosage; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D011446:Prospective Studies; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
D003366:Cosyntropin; D003009:Clorazepate Dipotassium; D003907:Dexamethasone; D004155:Diphenhydramine; D008787:Metoclopramide; D002945:Cisplatin
Essai phase III comparant l'activité anti-émétique du tétracosactide à la dexaméthasone employés en association avec le metoclopramide, la diphénhydramine et le clorazépate au cours de chimiothérapies comportant du cisplatine.